ReviewClinical ophthalmology (Auckland, N.Z.)2014
Pharmacotherapy for uveitis: current management and emerging therapy.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 85 citations in OpenAlex.
- Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.World journal of experimental medicine · 2025Review
- Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.Journal of ophthalmic inflammation and infection · 2024Article
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis.Korean journal of ophthalmology : KJO · 2023Article
- Comprehensive LncRNA and Potential Molecular Mechanism Analysis in Noninfectious Uveitis.Translational vision science & technology · 2023Article
- Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.Frontiers in immunology · 2023Review
- Article
- Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.Journal of ophthalmic inflammation and infection · 2022Article
- Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.Journal of inflammation research · 2022Review
- Annexin A1 Mimetic Peptide and Piperlongumine: Anti-Inflammatory Profiles in Endotoxin-Induced Uveitis.Cells · 2021Article
- A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value.Journal of multidisciplinary healthcare · 2021Article
- Recent advances in the management of non-infectious posterior uveitis.International ophthalmology · 2020Review
- Chronic active Epstein-Barr virus infection manifesting as coronary artery aneurysm and uveitis.Virology journal · 2020Article
- Hypomethylation of Notch1 DNA is associated with the occurrence of uveitis.Clinical and experimental immunology · 2020Article
- The effectiveness and safety of Chinese medicines for the treatment of uveitis: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.International journal of ophthalmology · 2020Article
- Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.Molecules (Basel, Switzerland) · 2019Article
- AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells.Journal of autoimmunity · 2019Article
- Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2019Article
- Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.